What is curcumin and how is it different from turmeric?

This is the single most important distinction to understand before evaluating any turmeric or curcumin supplement.

Turmeric is a spice — the dried, ground root of the plant Curcuma longa. It gives curry its yellow colour, and it has been used in traditional cooking and Ayurvedic practice for centuries. When people talk about "turmeric benefits," they are usually referring to the biological activity of curcumin, not the spice itself.

Curcumin is a specific group of polyphenolic compounds called curcuminoids. It is the most studied bioactive constituent of turmeric — but it makes up only 2–5% of turmeric root by weight. A teaspoon of ground turmeric (roughly 3g) contains approximately 60–150mg of curcuminoids, and the vast majority of that is poorly absorbed.

This matters because the clinical trials that have produced meaningful results use concentrated curcumin extracts — not turmeric powder. A supplement standardised to 50% curcuminoids delivers a dose that is fundamentally different from sprinkling turmeric on food. The two are not interchangeable, and conflating them leads to unrealistic expectations about what dietary turmeric can do.

Why is bioavailability the central challenge?

Curcumin has notoriously poor oral bioavailability. This is not a minor footnote — it is the defining limitation of the compound and the reason most over-the-counter turmeric capsules are unlikely to deliver meaningful systemic levels.

As reviewed by Anand et al. (2007), the problems are threefold:

This is why clinical trials overwhelmingly use enhanced formulations rather than raw curcumin powder. Common strategies include combining curcumin with piperine (black pepper extract) to inhibit metabolic enzymes, encapsulating it in liposomes or phospholipid complexes, or using nanoparticle delivery systems. Each approach attempts to solve the same fundamental problem: getting enough curcumin into the bloodstream to have a biological effect.

PARTICULAR's approach uses enteric-coated microgranules. Each granule has a protective coating that survives stomach acid, preventing gastric degradation and delivering curcumin to the intestine where absorption occurs. This addresses the acid-stability component of the bioavailability challenge — though it is important to be honest that no oral delivery system fully overcomes curcumin's inherent metabolic limitations.

What does the clinical evidence show for joint function and mobility?

Curcumin does not hold any EU-authorised health claims under EU Regulation 432/2012 (retained in UK law). No claim can be made that curcumin "supports joint health" or "maintains normal joint function." What follows is a summary of clinical trial evidence — not regulatory-approved wording.

Daily et al. (2016) published a systematic review and meta-analysis of randomised clinical trials examining turmeric extracts and curcumin for joint-related outcomes. Across eight RCTs, the authors found that curcumin extracts (typically around 1,000mg per day) were associated with statistically significant changes in pain and physical function scores compared to placebo, as measured by WOMAC and VAS scales. The authors concluded that the evidence supports the efficacy of turmeric extract at approximately 1,000mg/day of curcumin for joint-related outcomes.

Henrotin et al. (2019) conducted a double-blind, multicentre, randomised, placebo-controlled, three-arm trial with 150 participants experiencing knee discomfort. Both low and high doses of a bio-optimised Curcuma longa extract showed a greater decrease in patient-reported global disease activity assessment compared to placebo over 90 days.

These results are promising, but context matters. Most positive trials used enhanced bioavailability formulations, and the effect sizes, while statistically significant, are typically modest. Clinical trial evidence suggests curcumin may support comfort and mobility in individuals experiencing joint stiffness, but it is not a treatment for any joint condition.

For a broader overview of the evidence for joint-related nutrients, see our guide on supplements for joint pain.

What does the evidence show for exercise recovery and muscle soreness?

Delayed onset muscle soreness (DOMS) — the stiffness and discomfort that peaks 24–72 hours after unaccustomed exercise — has been the subject of several curcumin supplementation trials.

Nicol et al. (2015) conducted a double-blind, randomised, controlled crossover trial with 17 men examining the effect of oral curcumin (2.5g twice daily) on muscle soreness following heavy eccentric exercise. At 24 and 48 hours post-exercise, participants in the curcumin group showed moderate to large reductions in pain during single-leg squat and gluteal stretch, alongside small reductions in creatine kinase activity (a marker of muscle damage). The authors concluded that curcumin supplementation "likely attenuates" DOMS.

Drobnic et al. (2014) used a lecithin-based curcumin delivery system (designed to improve bioavailability) in a randomised, placebo-controlled trial examining muscle soreness after eccentric exercise. Participants receiving curcumin reported lower pain intensity, and the researchers observed differences in markers associated with muscle damage.

The evidence here is early-stage. Sample sizes are small, and different trials use different curcumin formulations at different doses, making direct comparison difficult. Research indicates that curcumin supplementation may reduce subjective soreness following intense exercise, but these findings need replication in larger trials before firm conclusions can be drawn.

What does the evidence show for mood and cognitive function?

This area requires particularly careful framing. Curcumin is not a treatment for depression or any mental health condition. No EU-authorised health claim exists for curcumin in relation to mood, cognition, or psychological function.

That said, one well-designed clinical trial is worth noting.

Lopresti et al. (2014) conducted a randomised, double-blind, placebo-controlled trial with 56 individuals diagnosed with major depressive disorder. Participants received either curcumin (500mg twice daily) or placebo for eight weeks. The study found that curcumin was associated with greater improvements in depressive symptom scores compared to placebo, with effects becoming apparent from weeks four to eight.

This is a single trial with a modest sample size. The authors themselves described the results as providing "partial support" for curcumin's potential in this population. It does not establish that curcumin is effective for depression, and it certainly does not mean that a curcumin supplement can replace psychiatric treatment or professional advice. Anyone experiencing symptoms of depression should consult a healthcare professional.

The result is noted here for completeness and scientific transparency — not as a basis for any health claim.

What can curcumin not claim?

It is worth being explicit about the regulatory and evidence boundaries.

No EU-authorised health claims exist for curcumin. Under EU Regulation 432/2012 (retained in UK law), curcumin cannot legally claim to contribute to normal joint function, immune function, cognitive function, or any other health outcome. It sits in the same regulatory category as CoQ10, ashwagandha, and MSM — ingredients with clinical trial evidence but without authorised claims.

Curcumin does not "fight inflammation." While in vitro studies have examined curcumin's interaction with inflammatory pathways, extrapolating from cell culture to whole-body claims is not scientifically valid. The phrase "natural anti-inflammatory" — ubiquitous in supplement marketing — is not supported by an authorised claim and oversimplifies the biology.

Curcumin does not prevent cancer. Preclinical research exists, but no clinical trial has established curcumin as a cancer-preventive agent in humans, and implying otherwise would be both inaccurate and irresponsible.

Any supplement brand making these claims about curcumin is either unaware of or disregarding the regulations that exist to protect consumers.

How does PARTICULAR's curcumin differ from a turmeric capsule?

Most turmeric capsules on the market contain ground turmeric root — the same 2–5% curcuminoid content you would find in the spice jar. Some are standardised to a higher curcuminoid percentage, but the delivery format and dosing precision vary widely.

PARTICULAR's curcumin (code PAR26) differs in three specific ways:

Standardised extract at 50% curcuminoids. The raw material is Curcuma longa extract standardised to 50% curcuminoids — not raw turmeric powder. This is approximately 10–25 times the curcuminoid concentration of whole turmeric.

Enteric-coated microgranule delivery. Each curcumin granule is individually coated with an enteric layer that resists stomach acid. This protects the compound through the gastric environment and targets release to the intestine. The microgranule format — 0.7–1.2mm spherical particles — also ensures that curcumin is delivered in its own separate granules, avoiding competitive inhibition with other nutrients at absorption sites.

Personalised dosing from 100–246mg. Your dose is determined by your responses to the questionnaire — not by a fixed one-size-fits-all capsule. The algorithm considers multiple factors across five dimensions to calculate whether curcumin is included in your formula and at what dose.

It is worth noting that PARTICULAR does not use piperine (black pepper extract) as a bioavailability enhancer. Some curcumin supplements combine curcumin with piperine, which inhibits certain metabolic enzymes to increase curcumin absorption. PARTICULAR's approach relies instead on the enteric-coated microgranule delivery system to protect curcumin through the stomach.

Build my formula →

From £79/month · exact cost shown before you commit · cancel any time

Key takeaways

  1. Curcumin and turmeric are not the same thing. Curcuminoids make up only 2–5% of turmeric by weight — eating turmeric in food provides negligible curcumin.

  2. Bioavailability is the central challenge. Raw curcumin is poorly absorbed, rapidly metabolised, and quickly eliminated. Any serious curcumin supplement must address this.

  3. Clinical trial evidence suggests curcumin may support joint comfort and mobility, with meta-analyses of RCTs showing statistically significant changes in pain and function scores.

  4. Early-stage evidence indicates curcumin supplementation may reduce subjective muscle soreness following intense exercise, though sample sizes remain small.

  5. One RCT in individuals with major depressive disorder found curcumin associated with improvements in symptom scores — but this does not mean curcumin treats depression.

  6. No EU-authorised health claims exist for curcumin. It cannot claim to support joints, reduce inflammation, prevent cancer, or contribute to any specific health outcome under UK regulations.

  7. PARTICULAR uses Curcuma longa extract standardised to 50% curcuminoids, delivered in enteric-coated microgranules at personalised doses of 100–246mg.

Sources cited in this article: